Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

IJIR publishes special/guest-edited issues and topical collections. The peer review process for articles included in topical collections/special issues is the same as the peer review process of the journal in general. Additionally, if the Guest Editors author an article in their topical collection/special issue, they will not handle the peer review process.​

Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study

International Journal of Impotence Research volume 18, pages 164–169 (2006)Cite this article

Abstract

We evaluate the efficacy and safety of citalopram, a potent and highly selective serotonin reuptake inhibitor (SSRI) antidepressant, in patients with premature ejaculation (PE). In total, 58 potent men with PE were included in the study. Patients were randomly assigned to receive 20 mg oral daily citalopram (group 1, n=29) or placebo (group 2, n=29), during a 12-week period for each agent. Pretreatment evaluation included history and physical examination, intravaginal ejaculatory latency time (IVELT) evaluation, International Index of Erectile Function (IIEF) and Meares–Stamey test. The efficacy of two treatments was assessed every 2 weeks during treatment, at the end of study and in 3- and 6-month follow-up after cessation of treatment, using responses to IIEF, IVELT evaluation, mean intercourse satisfaction domain, mean weekly coitus episodes and adverse drug effects. The trial was completed by 51 (88%) men. Analysis revealed a difference in the evolution of IVELT delay over time (P<0.001). The IVELT after citalopram and placebo gradually increased from 32 and 28 s to approximately 268 and 38 s, respectively. The mean weekly intercourse episodes increased from pretreatment values of 1.3 and 1.2 to 2.4 and 1.4, for citalopram and placebo, respectively (P<0.05). Baseline mean intercourse satisfaction domain values of IIEF 10 and 11 reached to 16 and 10 at 12-week treatment in groups 1 and 2, respectively (P<0.05). Mean IVELT in group 1 was 210 and 198 s at 3- and 6-month follow-up, while in group 2 it was 27 and 25 s (P<0.001), respectively. At 3- and six-month intercourse satisfaction domain values of IIEF were 15 and 14 in group 1 and 10 and 10 (P<0.05) in group 2, respectively. Group 1 patients reported a significantly higher number of intercourse episodes per week (P<0.05). Mean number of adverse events was 12 for citalopram and 4 for placebo (P<0.05). In conclusion, these results indicate that citalopram has significantly better results in terms of IVELT and intercourse satisfaction versus placebo. Further studies with different dosages and treatment regimens are necessary to draw final conclusions on the efficacy of this drug in PE and to prolong the efficacy.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Spector IP, Carey MP . Incidence and prevalence of sexual dysfunctions. A critical review of the empirical literature. Arch Sex Behav 1990; 19 (4): 389–408.

    Article  CAS  Google Scholar 

  2. Laumann EO, Paik A, Rosen RC . Sexual dysfunction in the United States: prevalence and predictors. JAMA 1999; 28: 537–544.

    Article  Google Scholar 

  3. Nettelbladt P, Uddenberg N . Sexual dysfunction and sexual satisfaction in 58 married Swedish men. J Psychosom Res 1979; 23: 141–147.

    Article  CAS  Google Scholar 

  4. Frank E, Anderson C, Rubinstein D . Frequency of sexual dysfunction in ‘normal’ couples. N Engl J Med 1978; 299: 111–115.

    Article  CAS  Google Scholar 

  5. Olivier B, Van Oorschot R, Waldinger MD . Serotonin, serotonergic receptors, selective serotonin reuptake inhibitors and sexual behaviour. Int Clin Psychopharmacol 1998; 13 (Suppl 6): S9–S14.

    Article  Google Scholar 

  6. Waldinger MD, Zwinderman AH, Olivier B . Antidepressants and ejaculation: a double-blind, randomized, placebo-controlled, fixed-dose study with paroxetine, sertraline, and nefazodone. J Clin Psychopharmacol 2001; 21: 293–297.

    Article  CAS  Google Scholar 

  7. Kara H, Aydın S, Agargun MY, Odabas O, Yilmaz Y . The efficacy of fluoxetine in the treatment of premature ejaculation: a double-blind placebo controlled study. J Urol 1996; 156: 1631–1632.

    Article  CAS  Google Scholar 

  8. Lee HS, Song DH, Kim C-H, Choi HK . An open clinical trial of fluoxetine in the treatment of premature ejaculation. J Clin Psychopharmacol 1996; 16: 379–382.

    Article  CAS  Google Scholar 

  9. Pollack MH, Reiter S, Hammerness P . Genitourinary and sexual adverse effects of psychotropic medication. Int J Psychiatry Med 1992; 22: 305–327.

    Article  CAS  Google Scholar 

  10. Leonard BE . Comparative pharmacologic properties of SSRIs in anxiety. In: Feighner JP, Boyer WF (eds.). Selective Serotonin Reuptake Inhibitors: Advances in Basic Research and Clinical Practice, 2nd edn. Chichester: John Wiley & Sons Ltd, 1996 pp. 35–62.

    Google Scholar 

  11. Waldinger MD, Zwinderman AH, Olivier B . SSRIs and ejaculation: a double-blind, randomized, fixed-dose study with paroxetine and citalopram. J Clin Psychopharmacol 2001; 21: 556–560.

    Article  CAS  Google Scholar 

  12. Atmaca M, Kuloglu M, Tezcan E, Ustundag B, Semercioz A . Serum leptin levels in patients with premature ejaculation before and after citalopram treatment. B J U Int 2003; 91: 252–254.

    Article  CAS  Google Scholar 

  13. Hyttel J . Citalopram – pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity. Prog Neuropsychopharmacol Biol Psychiatry 1982; 6: 277–295.

    Article  CAS  Google Scholar 

  14. Frink MC, Hennies HH, Englberger W, Haurand M, Wilffert B . Influence of tramadol on neurotransmitter systems of the rat brain. Rzneimittelforschung 1996; 46: 1029–1034.

    CAS  Google Scholar 

  15. Rosen RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A . The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology 1997; 49: 822–830.

    Article  CAS  Google Scholar 

  16. Kim SW, Paick JS . Short-term analysis of the effects of as needed use of sertraline at 5 pm for the treatment of premature ejaculation. Urology 1999; 54: 544–547.

    Article  CAS  Google Scholar 

  17. Waldinger MD . Towards evidence-based drug treatment research on premature ejaculation: a critical evaluation of methodology. IJIR 2003; 15: 309–313.

    CAS  Google Scholar 

  18. Mcmahon CG . Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. J Urol 1998; 159: 1935–1938.

    Article  CAS  Google Scholar 

  19. Manasia P, Pomerol J, Ribé N, Gutierrez del Pozo R, Garcia JA . Comparison of the efficacy and safety of 90 mg versus 20 mg fluoxetine in the treatment of premature ejaculation. J Urol 2003; 170: 164–165.

    Article  CAS  Google Scholar 

  20. Sae Chul K, Kyung Keun S . Efficacy and safety of fluoxetine, sertraline and clomipramine in patients with premature ejaculation: a double-blind, placebo controlled study. J Urol 1998; 159: 425–427.

    Article  Google Scholar 

  21. Montague DK, Jarow J, Broderick GA, Dmochowski R, Heaton J, Liu TF . AUA guideline on the pharmacologic management of premature ejaculation. J Urol 2004; 172: 290–294.

    Article  Google Scholar 

  22. Waldinger MD . The neurobiological approach to premature ejaculation. J Urol 2002; 168: 2359–2367.

    Article  Google Scholar 

  23. Olivier B, Bosch L, van Hest A . Preclinical evidence of the psychotropic profile of fluvoxamine. Pharmacopsychiatry 1993; 26 (Suppl 1): 2–9.

    Article  Google Scholar 

  24. Milne RJ, Goa KL . Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness. Drugs 1991; 41: 450–477.

    Article  CAS  Google Scholar 

  25. Romero L, Casanovas JM, Hervas I, Cortés R, Artigas F . Strategies to optimize the antidepressant action of selective serotonin reuptake inhibitors. In: Skolnick P (ed.), Antidepressants. New Pharmacological Strategies. Totowa, NJ: Humana Press, 1997, pp. 1–33.

    Google Scholar 

  26. Barton DL, Loprinzi CL, Novotny P, Shanafelt T, Sloan J, Wahner-Roedler D et al. Pilot evaluation of citalopram for the relief of hot flashes. J Supportive Oncol 2003; 1: 47–51.

    CAS  Google Scholar 

  27. Johnson S, Johnson FN (eds). Citalopram. Rev Contemp Pharmacother 1995; 6: 271–324.

    Google Scholar 

  28. Anderson GM, Bennett AJ, Weld KP, Pushkas JG, Ocame DM, Higley JD . Serotonin in cisternal cerebrospinal fluid of rhesus monkeys: basal levels and effects of sertraline administration. Psychopharmacology 2002; 161: 95–99.

    Article  CAS  Google Scholar 

  29. Waldinger MD . Effect of SSRI antidepressant on ejaculation: a double-blind, randomized, placebo-controlled study with fluoxetine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 1998b; 18: 274–281.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Urology Nephrology Research Center, Shaheed Beheshti University of Medical Sciences, Tehran, Iran

    M R Safarinejad & S Y Hosseini

Authors
  1. M R Safarinejad
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S Y Hosseini
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M R Safarinejad.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Safarinejad, M., Hosseini, S. Safety and efficacy of citalopram in the treatment of premature ejaculation: a double-blind placebo-controlled, fixed dose, randomized study. Int J Impot Res 18, 164–169 (2006). https://doi.org/10.1038/sj.ijir.3901384

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901384

Keywords

  • premature ejaculation
  • treatment
  • citalopram
  • serotonin
  • sexual dysfunction

This article is cited by

Search

Advanced search

Quick links